MedTrace Logo

Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin

NCT00481936 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-03-23

No results posted yet for this study

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of VB6-845 and to evaluate the safety and tolerability of VB6-845 when administered as a monotherapy IV infusion to patients with advanced solid tumour of epithelial origin.

Conditions

  • Neoplasms, Glandular and Epithelial

Interventions

DRUG

VB6-845

Intravenous infusion once weekly for 4 weeks

Sponsors & Collaborators

  • Sesen Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Wendy Cuthbert · Sesen Bio, Inc.

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Georgia
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00481936 on ClinicalTrials.gov